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Letters to the Editor1155 adult patients undergoing car-
diac surgery, found that both b-
blockers and volatile anesthetics are
potentially influential factors in cardi-
oprotection by RIPC, a finding
confirmed in univariate metaregres-
sion and subgroup analyses. The role
of b-blockers remained significant in
the CABG subgroup (Figure 1). In
addition, the potential interference of
b-blockers was independent of vola-
tile anesthetics in the subsequent
multivariate analysis (Table 1). More-
over, previous studies that used animal
hearts or human isolated atrial trabec-
ulae have suggested that b-blockers
could abolish the cardioprotection of
ischemic or anesthetic precondition-
ing (see discussion in reference 4). In
addition, no cardiac benefit from
RIPC in CABG was observed in Luc-
chinetti and associates’ study,5 which
had a mean b-blocker proportion of
91%. These evidence suggested
greater significance of b-blockers in
the cardioprotective effect of RIPC,
which is thusmore important in the po-
tential interference with cardioprotec-
tion by RIPC.
Is it b-blockers or anesthetic
choice? The findings from my group
are based mainly on the aggregate
patient data. We are therefore inter-
ested to know whether this would
hold true for the individual patient
data in Kottenberg and colleagues’
study2 if multivariate linear regres-
sion analyses at least including
b-blockers and anesthetic choice
in a total of 72 patients were
performed.
Yang Liu, MDa
Li Ma, MDb
aDepartment of Intensive Care Unit
bCellular & Molecular Biology
Beijing Chest Hospital
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Beijing, China
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THE AMERICAN COLLEGE OF
SURGERY ONCOLOGY GROUP
Z0030 TRIAL
To the Editor:
We read with great interest the report
by Darling and colleagues1 regarding
the impact onpatient survival ofmedias-
tinal lymph node dissection (MLND)
during lung cancer surgery. This study
focused strictly on whether MLND had
any impact on survival relative to reli-
able mediastinal lymph node sampling.
This is oneof themost challengingques-
tions in thoracic surgery; to answer
it, Darling and colleagues1 prepared
and executed an elaborate protocol.
Although the result was negative—that
is, MLND did not show any survival
benefit relative to mediastinal lymph
node sampling—the data acquired
from this studyare of great clinical value
for benchmarking. Whereas this study
was carried out by authorized expert
thoracic surgeons, our real-world prac-
tice can be assessed by comparing our
results with the published outcomes of
morbidity and mortality.2
Darling and colleagues1 reported
285 recurrences, including 54 local,Cardiovascular Surgery c November 2074 regional, and 225 distant recur-
rences, in the eligible subject popula-
tion. Although it is unclear whether
each recurrence number was counted
by case or site, we are very interested
in the definition of the terms, namely,
local, regional, and distant recurrence.
Because the local and regional recur-
rence rates vary according to the de-
finition of the terms3 and a standard
definition does not currently exist, we
would like investigators to specify their
definitions of these terms. Several loca-
tions should be considered as the recur-
rence sites in the definition, including
bronchial stump, ipsilateral hilum, in-
terlobar staple line, ipsilateral medi-
astinal lymph node, ipsilateral lung
parenchyma, ipsilateral thoracic cavity
(pleural dissemination and malignant
pleural effusion), contralateral medias-
tinal/hilum lymph node, supraclavicu-
lar lymph node, contralateral lung
parenchyma, chest wall, and malignant
pericardial effusion.We hope that stan-
dard definitions for recurrence siteswill
be established in the near future.
The American College of Surgery
Oncology Group Z0030 trial results
continue to produce new findings.4
We believe the full utilization of this
landmark database is important to
improve clinical practice and future
studies.
Hideo Ichimura, MD
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j.jtcvs.2013.04.048PROSTHETIC AORTIC VALVE
EVALUATION: SHOULD THE
ASSESSMENT OF
HEMODYNAMIC
PERFORMANCE DURING
EXERCISE COMPLETE THE
ANALYSIS?
To the Editor:
In a recent publication, Suri and
colleagues1 evaluated the hemody-
namic performance of the latest
generation of biologic aortic valve
prostheses. The results evidenced
small but consistent early postopera-
tive hemodynamic differences among
current third-generation bioprostheses
(Edwards Magna, Sorin Mitroflow,
and St Jude Epic). We read the article
with interest and were also impressed
byDrDavid’s comment in themeeting
discussion. We congratulate Suri and
colleagues1 on this study; however,
we would like to add some comments.
First, Suri and colleagues1 likely
included in their study any type of
aortic valve disease, which could be
misleading for comparative results.
Aortic stenosis, aortic incompetence,
and their combination have differ-
ences in physiology, histology, and
anatomy, leading to different beha-
viors after the valve replacement.
Second, patients were assessed for
hemodynamic performance before
hospital discharge. This is contrary
to previous studies, which indicate
that in vivo values should be taken at
1-year follow-up because gradients
may change during the first postoper-
ative year, with significant impact onThe Journaleither the hemodynamic results or
the exercise capacity.2
Third, any realistic assessment of
hemodynamic behavior of a pros-
thesis should include evaluation
during exercise. Results obtained
under stress are by far more suitable
to evaluate the performance of a
valve type than hemodynamic data
obtained at rest, and they also reflect
more closely the situation in daily
life. In this regard, Gerosa and
colleagues3 used the Sheffield pulse
duplicator to demonstrate in vitro
that different prostheses perform
differently in different hemodynamic
circumstances. In vivo evaluations
are even more difficult. Stress-
induced echocardiographic assess-
ment could be hindered by several
confounding factors: heart rate,
cardiac output, left ventricle diastolic
pattern, hypertension, reduced sys-
temic arterial compliance, and so on.
In a recent study, we evaluated by
echocardiography the hemodynamic
performance at rest and during exer-
cise of 2 different aortic prostheses
of similar size implanted in patients
who underwent surgery for pure aortic
stenosis.4 Although the study
compared a mechanical valve with a
porcine bioprosthesis, our results
validated the technical procedures as
model for evaluations under stress.
As we were aware that the sole
measurement of gradients does
not entirely represent the complex
function of a valve during physical
exercise, we also analyzed the
stress-induced abnormalities of the
cardiac cycle 1 year after aortic valve
replacement. As is widely known, the
total cardiac cycle duration is alge-
braically dependent on the heart rate
(60,000 ms/heart rate), which is the
major determinant affecting diastolic
and systolic duration. Systolic time
has a negative linear correlation with
heart rate. Diastolic time is longer at
low heart rates and decreases more
markedly than systolic time during
exercise. Transprosthetic gradient is
a function of both diastolic durationof Thoracic and Cardiovascular Surgerand systolic/diastolic ratio, which
depends on a number of cofactors
but could also be attributed to the
flexibility of the stent and the geomet-
ric design of the bioprostheses.
These factors interfere with the
delicate physiologic mechanism of
active annulus motion and aortic root
expansion at each phase of the cardiac
cycle, especially during exercise. This
is more valid for mechanical valves
and for 19- to 23-mm bioprostheses.
A meaningful evaluation of a bio-
prosthesis should therefore further
consider the stent flexibility during
exercise and the effective tolerability
of its distortion when upsized.
Vito Mannacio, MD
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To the Editor:
Todman and associates1 recently
described favorable outcomes aftery c Volume 146, Number 5 1307
